MitraClip 作为晚期心衰继发性二尖瓣反流患者心脏移植桥接策略的 1 年结局:国际 MitraBridge 注册研究
本研究基于国际多中心(17 中心)注册的 119 例中度以上继发性二尖瓣反流合并晚期心衰患者(中位年龄 58 岁,中位左室射血分数 26%),评估 MitraClip 作为心脏移植桥接策略的效果。手术成功率为 87.5%,30 天生存率为 100%;1 年时免于复合主要终点(死亡、紧急心脏移植或左室辅助装置植入、首次因心衰再住院)的 Kaplan-Meier 估计值为 64%。结论认为该桥接策略安全,约三分之二患者 1 年内未发生不良事件,但结果属探索性、需进一步研究验证。
要点
- MitraClip 作为心脏移植桥接策略手术成功率 87.5%,30 天生存率 100%。
- 1 年免于死亡、紧急移植/左室辅助装置或心衰再住院的估计值为 64%。
- 末次随访时 23.5% 患者因临床改善已无心脏移植指征。
核心结论
- 在晚期心衰合并显著二尖瓣反流患者中,MitraClip 作为心脏移植桥接策略是安全的,约三分之二患者 1 年内免于不良事件。
- 作者认为结果属探索性与假设生成性质,需进一步研究经皮介入用于高危晚期心衰患者。
研究设计与样本
- 国际、多中心(17 个中心)注册研究,共纳入 119 例中度至重度或重度继发性二尖瓣反流合并晚期心衰患者,中位年龄 58 岁,中位左室射血分数 26%。
- 按桥接标准分为三组:在移植名单组(n=31)、桥接至决策组(n=54)、桥接至候选资格组(n=34)。
主要发现
- 手术成功率为 87.5%,30 天生存率为 100%。
- 1 年时复合主要终点(死亡、紧急心脏移植或左室辅助装置植入、首次因心衰再住院)的 Kaplan-Meier 免于发生估计值为 64%。
- 末次随访(中位 532 天)时,15% 患者接受择期移植,15.5% 仍在或可被纳入心脏移植等待名单,23.5% 因临床改善已无心脏移植指征。
临床怎么用
- 对于等待心脏移植的晚期心衰合并显著继发性二尖瓣反流患者,可考虑 MitraClip 作为桥接策略以稳定病情。
- 桥接后可定期再评估心脏移植指征,部分患者临床改善后可能不再需要移植。
局限性
- 结果为探索性、假设生成性质,需进一步研究验证。
- 原文摘要未报告对照设计与长期结局数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients awaiting heart transplantation (HTx) often need bridging therapies to reduce worsening and progression of underlying disease. Limited data are available regarding the use of the MitraClip procedure in secondary mitral regurgitation for this clinical condition. METHODS: We evaluated an international, multicenter (17 centers) registry including 119 patients (median age: 58 years) with moderate-to-severe or severe secondary mitral regurgitation and advanced heart failure (HF) (median left ventricular ejection fraction: 26%) treated with MitraClip as a bridge strategy according to 1 of the following criteria: (1) patients active on HTx list (in list group) (n = 31); (2) patients suitable for HTx but awaiting clinical decision (bridge to decision group) (n = 54); or (3) patients not yet suitable for HTx because of potentially reversible relative contraindications (bridge to candidacy group) (n = 34). RESULTS: Procedural success was achieved in 87.5% of cases, and 30-day survival was 100%. At 1 year, Kaplan-Meier estimates of freedom from the composite primary end-point (death, urgent HTx or left ventricular assist device implantation, first rehospitalization for HF) was 64%. At the time of last available follow-up (median: 532 days), 15% of patients underwent elective transplant, 15.5% remained or could be included in the HTx waiting list, and 23.5% had no more indication to HTx because of clinical improvement. CONCLUSIONS: MitraClip procedure as a bridge strategy to HTx in patients with advanced HF with significant mitral regurgitation was safe, and two thirds of patients remained free from adverse events at 1 year. These findings should be considered exploratory and hypothesis-generating to guide further study for percutaneous intervention in high-risk patients with advanced HF.
引用
- Godino C, Munafò A, Scotti A, et al. MitraClip in secondary mitral regurgitation as a bridge to heart transplantation: 1-year outcomes from the International MitraBridge Registry. J Heart Lung Transplant. 2020. PMID: 33008726. doi:10.1016/j.healun.2020.09.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。